참고문헌
- Lee AJ, Suh CH, Kim KW. Evolution of clinical trial imaging and co-clinical imaging. In: Nishino M, eds. Therapy response imaging in oncology. Cham: Springer International Publishing, 2020:239-253
- United States. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research. Clinical Trial Imaging Endpoint Process Standards: Guidance for Industry [accessed on July 26, 2023]. Available at: https://www.fda.gov/regulatory-information/search-fdaguidance-documents/clinical-trial-imaging-endpoint-processstandards-guidance-industry
- Beaumont H, Iannessi A, Wang Y, Voyton CM, Cillario J, Liu Y. Blinded Independent Central Review (BICR) in new therapeutic lung cancer trials. Cancers (Basel) 2021;13:4533
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247 https://doi.org/10.1016/j.ejca.2008.10.026
- Hyung J, Kim I, Kim KP, Ryoo BY, Jeong JH, Kang MJ, et al. Treatment with liposomal urinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial. JAMA Oncol 2023;9:692-699 https://doi.org/10.1001/jamaoncol.2023.0016